Abstract
Antipyrine elimination kinetics were measured in psychotic patients receiving either long-term chloropromazine or fluphenazine decanoate therapy and in non-medicated control subjects. Patients receiving chlorpromazine metabolised antipyrine faster than the controls while, in patients receiving fluphenazine decanoate, there was no change. The results suggest that long-term chlorpromazine therapy induced the activity of drug-metabolising enzymes, whereas fluphenazine decanoate therapy had no effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abshagen, U., Rennekamp, H., Luszpinski, G.: Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment. Eur. J. Pharmacol. 11, 169–176 (1977)
Chen, W., Vrindten, P. A., Dayton, P. G., Burns, J. J.: Accelerated aminopyrine metabolism in human subjects pretreated with phenylbutazone. Life Sci. 2, 35–42 (1962)
Cucinell, S. A., Conney, A. H., Sansur, M., Burns, J. J.: Drug interactions in man. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (Dicoumarol) and diphenylhydantoin (Dilantin). Clin. Pharmacol. Ther. 6, 420–429 (1965)
Curry, S. H., Whelpton, R., de Schepper, P. J., Vranckx, S., Schiff, A. A.: Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br. J. Clin. Pharmacol. 7, 325–331 (1979)
Dayton, P. G., Tarcan, Y., Chenkin, T., Weiner, M.: The influence of barbiturates on coumarin plasma levels and prothrombin response. J. Clin. Invest. 40, 1797–1802 (1961)
Harman, A. W., Priestly, B. G., Frewin, D. B.: A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis. Clin. Exp. Pharmacol. Physiol. 4, 593–596 (1977)
Harman, A. W., Penhall, R. K., Priestly, B. G., Frewin, D. B., Phillips, P. J., Clarkson, A. R.: Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy. Aust. N.Z. J. Med. 7, 385–390 (1977a)
Kato, R., Ciesara, E.: Increase of pentobarbitone metabolism induced in rats pretreated with some centrally acting compounds. Br. J. Pharmacol. 18, 29–38 (1962)
Kato, R., Vassanelli, P.: Induction of increased meprobamate metabolism in rats pretreated with some neuroleptic drugs. Biochem. Pharmacol. 11, 779–794 (1962)
Latham, A. N., Padgham, C., Henryk-Gutt, R.: The effect of fluphenazine decanoate (Modecate) on hepatic microsomal activity in man. Br. J. Clin. Pharmacol. 1, 277–278 (1974)
Loga, S., Curry, S., Lader, M.: Interactions of orphenadrine and phenobarbitone with chlorpromazine: Plasma concentrations and effects in man. Br. J. Clin. Pharmacol. 2, 197–208 (1975)
Majumbar, S. K., Kakad, P. P.: Effect of prolonged therapy with neuroleptics on hepatic microsomal enzyme activity in schizophrenic patients. Postgrad. Med. J. 54, 789–790 (1978)
Perucca, E.: Clinical consequences of microsomal enzyme induction by antiepileptic drugs. Pharmacol. Ther. C. 2, 285–314 (1978)
Stevenson, I. H., O'Malley, K., Turnbull, M. J., Ballinger, B. R.: The effect of chlorpromazine on drug metabolism. J. Pharm. Pharmacol. 24, 577–578 (1972)
Stevenson, I. H.: Factors affecting antipyrine elimination. Br. J. Clin. Pharmacol. 4, 261–265 (1977)
Welch, R. M., De Angelis, R. L., Wingfield, M., Farmer, T. W.: Elimination of antipyrine from saliva as a measure of metabolism in man. Clin. Pharmacol. Ther. 18, 249–258 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harman, A.W., Frewin, D.B. & Priestly, B.G. Comparative enzyme-inducing effects of chlorpromazine and fluphenazine therapies in psychotic patients. Psychopharmacology 69, 35–37 (1980). https://doi.org/10.1007/BF00426518
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00426518